HEADER PROTEIN BINDING/ACTIVATOR 03-DEC-16 5U3W TITLE HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC TITLE 2 AGONIST 7 COMPND MOL_ID: 1; COMPND 2 MOLECULE: PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: LIGAND-BINDING DOMAIN; COMPND 5 SYNONYM: PPAR-DELTA,NUCI,NUCLEAR HORMONE RECEPTOR 1,NUC1,NUCLEAR COMPND 6 RECEPTOR SUBFAMILY 1 GROUP C MEMBER 2,PEROXISOME PROLIFERATOR- COMPND 7 ACTIVATED RECEPTOR BETA,PPAR-BETA; COMPND 8 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: PPARD, NR1C2, PPARB; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PET28A(+) KEYWDS PPARDELTA, LIGAND-BINDING DOMAIN, AGONIST, PROTEIN BINDING-ACTIVATOR KEYWDS 2 COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR C.-C.WU,T.J.BAIGA,M.DOWNES,J.J.LA CLAIR,A.R.ATKINS,S.B.RICHARD, AUTHOR 2 T.A.STOCKLEY-NOEL,M.E.BOWMAN,R.M.EVANS,J.P.NOEL REVDAT 6 09-OCT-24 5U3W 1 REMARK REVDAT 5 04-OCT-23 5U3W 1 HETSYN REVDAT 4 29-JUL-20 5U3W 1 COMPND REMARK HETNAM SITE REVDAT 4 2 1 ATOM REVDAT 3 05-APR-17 5U3W 1 JRNL REVDAT 2 29-MAR-17 5U3W 1 JRNL REVDAT 1 22-MAR-17 5U3W 0 JRNL AUTH C.C.WU,T.J.BAIGA,M.DOWNES,J.J.LA CLAIR,A.R.ATKINS, JRNL AUTH 2 S.B.RICHARD,W.FAN,T.A.STOCKLEY-NOEL,M.E.BOWMAN,J.P.NOEL, JRNL AUTH 3 R.M.EVANS JRNL TITL STRUCTURAL BASIS FOR SPECIFIC LIGATION OF THE PEROXISOME JRNL TITL 2 PROLIFERATOR-ACTIVATED RECEPTOR DELTA. JRNL REF PROC. NATL. ACAD. SCI. V. 114 E2563 2017 JRNL REF 2 U.S.A. JRNL REFN ESSN 1091-6490 JRNL PMID 28320959 JRNL DOI 10.1073/PNAS.1621513114 REMARK 2 REMARK 2 RESOLUTION. 1.80 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX 1.9PRE_1665 REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.80 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 42.68 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.340 REMARK 3 COMPLETENESS FOR RANGE (%) : 98.0 REMARK 3 NUMBER OF REFLECTIONS : 63935 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.193 REMARK 3 R VALUE (WORKING SET) : 0.192 REMARK 3 FREE R VALUE : 0.243 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 1.970 REMARK 3 FREE R VALUE TEST SET COUNT : 1259 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 42.6962 - 3.7435 0.99 7167 134 0.1480 0.2058 REMARK 3 2 3.7435 - 2.9715 1.00 7095 173 0.1726 0.2287 REMARK 3 3 2.9715 - 2.5960 1.00 7148 109 0.1966 0.2537 REMARK 3 4 2.5960 - 2.3586 1.00 7057 161 0.1985 0.2269 REMARK 3 5 2.3586 - 2.1896 1.00 7059 138 0.2032 0.2683 REMARK 3 6 2.1896 - 2.0605 1.00 7112 142 0.2177 0.2517 REMARK 3 7 2.0605 - 1.9573 1.00 7063 150 0.2424 0.2491 REMARK 3 8 1.9573 - 1.8721 0.98 6921 130 0.2971 0.3555 REMARK 3 9 1.8721 - 1.8000 0.86 6054 122 0.3208 0.3860 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : NULL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.230 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 27.880 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.011 4602 REMARK 3 ANGLE : 1.289 6219 REMARK 3 CHIRALITY : 0.056 710 REMARK 3 PLANARITY : 0.006 777 REMARK 3 DIHEDRAL : 13.731 1719 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 2 REMARK 3 TLS GROUP : 1 REMARK 3 SELECTION: ( CHAIN A AND RESID 170:440 ) REMARK 3 ORIGIN FOR THE GROUP (A): -15.8920 0.7332 125.3059 REMARK 3 T TENSOR REMARK 3 T11: 0.1131 T22: 0.1045 REMARK 3 T33: 0.1186 T12: 0.0158 REMARK 3 T13: -0.0216 T23: 0.0238 REMARK 3 L TENSOR REMARK 3 L11: 1.6846 L22: 1.5674 REMARK 3 L33: 2.4956 L12: 0.0173 REMARK 3 L13: -0.6785 L23: -0.1492 REMARK 3 S TENSOR REMARK 3 S11: 0.0138 S12: -0.0568 S13: -0.0528 REMARK 3 S21: -0.1266 S22: -0.0126 S23: -0.0476 REMARK 3 S31: -0.0454 S32: 0.1282 S33: -0.0011 REMARK 3 TLS GROUP : 2 REMARK 3 SELECTION: ( CHAIN B AND RESID 174:441 ) REMARK 3 ORIGIN FOR THE GROUP (A): -13.8687 38.7765 114.2378 REMARK 3 T TENSOR REMARK 3 T11: 0.2553 T22: 0.1746 REMARK 3 T33: 0.1495 T12: 0.0019 REMARK 3 T13: 0.0005 T23: -0.0003 REMARK 3 L TENSOR REMARK 3 L11: 1.1618 L22: 1.0053 REMARK 3 L33: 4.1782 L12: 0.0610 REMARK 3 L13: -0.1613 L23: -0.8082 REMARK 3 S TENSOR REMARK 3 S11: 0.0480 S12: 0.0530 S13: 0.0743 REMARK 3 S21: -0.0669 S22: 0.0465 S23: 0.0424 REMARK 3 S31: -0.0749 S32: 0.1942 S33: -0.0790 REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 5U3W COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 06-DEC-16. REMARK 100 THE DEPOSITION ID IS D_1000225266. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 12-APR-16 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 7.5 - 8.8 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ALS REMARK 200 BEAMLINE : 8.2.2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 315R REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 85744 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.550 REMARK 200 RESOLUTION RANGE LOW (A) : 94.810 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 84.0 REMARK 200 DATA REDUNDANCY : 3.600 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 5.2000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.55 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.58 REMARK 200 COMPLETENESS FOR SHELL (%) : 42.1 REMARK 200 DATA REDUNDANCY IN SHELL : 1.20 REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 0.500 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: 1GWZ REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 57.21 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.87 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: BIS-TRIS PROPANE, POTASSIUM CHLORIDE, REMARK 280 PEG 8000, 1,2-PROPANDIOL, EDTA, DTT, PH 7.5, VAPOR DIFFUSION, REMARK 280 HANGING DROP, TEMPERATURE 277.15K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 47.40500 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ALA A 205 REMARK 465 SER A 206 REMARK 465 HIS A 207 REMARK 465 THR A 208 REMARK 465 TYR A 441 REMARK 465 PRO B 170 REMARK 465 GLN B 171 REMARK 465 VAL B 172 REMARK 465 ALA B 173 REMARK 465 GLY B 203 REMARK 465 LYS B 204 REMARK 465 ALA B 205 REMARK 465 SER B 206 REMARK 465 HIS B 207 REMARK 465 THR B 208 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O1 PGO A 506 O HOH A 601 2.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15 REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375 REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS. REMARK 500 REMARK 500 DISTANCE CUTOFF: REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE REMARK 500 O HOH A 727 O HOH B 620 2547 2.15 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LYS A 239 -57.42 -126.48 REMARK 500 ASN A 366 77.31 -112.62 REMARK 500 GLU A 424 68.40 -112.60 REMARK 500 ASN B 366 78.90 -105.60 REMARK 500 GLU B 424 61.55 -114.87 REMARK 500 ASP B 439 54.61 -118.66 REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 5U3Q RELATED DB: PDB REMARK 900 RELATED ID: 5U3R RELATED DB: PDB REMARK 900 RELATED ID: 5U3S RELATED DB: PDB REMARK 900 RELATED ID: 5U3T RELATED DB: PDB REMARK 900 RELATED ID: 5U3U RELATED DB: PDB REMARK 900 RELATED ID: 5U3V RELATED DB: PDB REMARK 900 RELATED ID: 5U3X RELATED DB: PDB REMARK 900 RELATED ID: 5U3Y RELATED DB: PDB REMARK 900 RELATED ID: 5U3Z RELATED DB: PDB REMARK 900 RELATED ID: 5U40 RELATED DB: PDB REMARK 900 RELATED ID: 5U41 RELATED DB: PDB REMARK 900 RELATED ID: 5U42 RELATED DB: PDB REMARK 900 RELATED ID: 5U44 RELATED DB: PDB REMARK 900 RELATED ID: 5U45 RELATED DB: PDB REMARK 900 RELATED ID: 5U46 RELATED DB: PDB DBREF 5U3W A 170 441 UNP Q03181 PPARD_HUMAN 72 343 DBREF 5U3W B 170 441 UNP Q03181 PPARD_HUMAN 72 343 SEQRES 1 A 272 PRO GLN VAL ALA ASP LEU LYS ALA PHE SER LYS HIS ILE SEQRES 2 A 272 TYR ASN ALA TYR LEU LYS ASN PHE ASN MET THR LYS LYS SEQRES 3 A 272 LYS ALA ARG SER ILE LEU THR GLY LYS ALA SER HIS THR SEQRES 4 A 272 ALA PRO PHE VAL ILE HIS ASP ILE GLU THR LEU TRP GLN SEQRES 5 A 272 ALA GLU LYS GLY LEU VAL TRP LYS GLN LEU VAL ASN GLY SEQRES 6 A 272 LEU PRO PRO TYR LYS GLU ILE SER VAL HIS VAL PHE TYR SEQRES 7 A 272 ARG CYS GLN CME THR THR VAL GLU THR VAL ARG GLU LEU SEQRES 8 A 272 THR GLU PHE ALA LYS SER ILE PRO SER PHE SER SER LEU SEQRES 9 A 272 PHE LEU ASN ASP GLN VAL THR LEU LEU LYS TYR GLY VAL SEQRES 10 A 272 HIS GLU ALA ILE PHE ALA MET LEU ALA SER ILE VAL ASN SEQRES 11 A 272 LYS ASP GLY LEU LEU VAL ALA ASN GLY SER GLY PHE VAL SEQRES 12 A 272 THR ARG GLU PHE LEU ARG SER LEU ARG LYS PRO PHE SER SEQRES 13 A 272 ASP ILE ILE GLU PRO LYS PHE GLU PHE ALA VAL LYS PHE SEQRES 14 A 272 ASN ALA LEU GLU LEU ASP ASP SER ASP LEU ALA LEU PHE SEQRES 15 A 272 ILE ALA ALA ILE ILE LEU CYS GLY ASP ARG PRO GLY LEU SEQRES 16 A 272 MET ASN VAL PRO ARG VAL GLU ALA ILE GLN ASP THR ILE SEQRES 17 A 272 LEU ARG ALA LEU GLU PHE HIS LEU GLN ALA ASN HIS PRO SEQRES 18 A 272 ASP ALA GLN TYR LEU PHE PRO LYS LEU LEU GLN LYS MET SEQRES 19 A 272 ALA ASP LEU ARG GLN LEU VAL THR GLU HIS ALA GLN MET SEQRES 20 A 272 MET GLN ARG ILE LYS LYS THR GLU THR GLU THR SER LEU SEQRES 21 A 272 HIS PRO LEU LEU GLN GLU ILE TYR LYS ASP MET TYR SEQRES 1 B 272 PRO GLN VAL ALA ASP LEU LYS ALA PHE SER LYS HIS ILE SEQRES 2 B 272 TYR ASN ALA TYR LEU LYS ASN PHE ASN MET THR LYS LYS SEQRES 3 B 272 LYS ALA ARG SER ILE LEU THR GLY LYS ALA SER HIS THR SEQRES 4 B 272 ALA PRO PHE VAL ILE HIS ASP ILE GLU THR LEU TRP GLN SEQRES 5 B 272 ALA GLU LYS GLY LEU VAL TRP LYS GLN LEU VAL ASN GLY SEQRES 6 B 272 LEU PRO PRO TYR LYS GLU ILE SER VAL HIS VAL PHE TYR SEQRES 7 B 272 ARG CYS GLN CME THR THR VAL GLU THR VAL ARG GLU LEU SEQRES 8 B 272 THR GLU PHE ALA LYS SER ILE PRO SER PHE SER SER LEU SEQRES 9 B 272 PHE LEU ASN ASP GLN VAL THR LEU LEU LYS TYR GLY VAL SEQRES 10 B 272 HIS GLU ALA ILE PHE ALA MET LEU ALA SER ILE VAL ASN SEQRES 11 B 272 LYS ASP GLY LEU LEU VAL ALA ASN GLY SER GLY PHE VAL SEQRES 12 B 272 THR ARG GLU PHE LEU ARG SER LEU ARG LYS PRO PHE SER SEQRES 13 B 272 ASP ILE ILE GLU PRO LYS PHE GLU PHE ALA VAL LYS PHE SEQRES 14 B 272 ASN ALA LEU GLU LEU ASP ASP SER ASP LEU ALA LEU PHE SEQRES 15 B 272 ILE ALA ALA ILE ILE LEU CYS GLY ASP ARG PRO GLY LEU SEQRES 16 B 272 MET ASN VAL PRO ARG VAL GLU ALA ILE GLN ASP THR ILE SEQRES 17 B 272 LEU ARG ALA LEU GLU PHE HIS LEU GLN ALA ASN HIS PRO SEQRES 18 B 272 ASP ALA GLN TYR LEU PHE PRO LYS LEU LEU GLN LYS MET SEQRES 19 B 272 ALA ASP LEU ARG GLN LEU VAL THR GLU HIS ALA GLN MET SEQRES 20 B 272 MET GLN ARG ILE LYS LYS THR GLU THR GLU THR SER LEU SEQRES 21 B 272 HIS PRO LEU LEU GLN GLU ILE TYR LYS ASP MET TYR MODRES 5U3W CME A 251 CYS MODIFIED RESIDUE MODRES 5U3W CME B 251 CYS MODIFIED RESIDUE HET CME A 251 18 HET CME B 251 18 HET B7G A 501 45 HET 7U1 A 502 64 HET B7G A 503 45 HET PGO A 504 26 HET PGO A 505 13 HET PGO A 506 13 HET PGO A 507 13 HET 7U1 B 501 64 HET PEG B 502 17 HETNAM CME S,S-(2-HYDROXYETHYL)THIOCYSTEINE HETNAM B7G HEPTYL BETA-D-GLUCOPYRANOSIDE HETNAM 7U1 6-(2-{[([1,1'-BIPHENYL]-4-CARBONYL)(CYCLOPROPYL) HETNAM 2 7U1 AMINO]METHYL}PHENOXY)HEXANOIC ACID HETNAM PGO S-1,2-PROPANEDIOL HETNAM PEG DI(HYDROXYETHYL)ETHER HETSYN B7G HEPTYL-BETA-D-GLUCOPYRANOSIDE; HEPTYL BETA-D-GLUCOSIDE; HETSYN 2 B7G HEPTYL D-GLUCOSIDE; HEPTYL GLUCOSIDE FORMUL 1 CME 2(C5 H11 N O3 S2) FORMUL 3 B7G 2(C13 H26 O6) FORMUL 4 7U1 2(C29 H31 N O4) FORMUL 6 PGO 4(C3 H8 O2) FORMUL 11 PEG C4 H10 O3 FORMUL 12 HOH *278(H2 O) HELIX 1 AA1 PRO A 170 PHE A 190 1 21 HELIX 2 AA2 THR A 193 GLY A 203 1 11 HELIX 3 AA3 ASP A 215 LEU A 226 1 12 HELIX 4 AA4 LEU A 231 LEU A 235 5 5 HELIX 5 AA5 GLU A 240 SER A 266 1 27 HELIX 6 AA6 ILE A 267 SER A 272 1 6 HELIX 7 AA7 PHE A 274 ALA A 295 1 22 HELIX 8 AA8 ALA A 306 GLY A 308 5 3 HELIX 9 AA9 ARG A 314 SER A 319 1 6 HELIX 10 AB1 PRO A 323 ALA A 340 1 18 HELIX 11 AB2 ASP A 344 LEU A 357 1 14 HELIX 12 AB3 ASN A 366 HIS A 389 1 24 HELIX 13 AB4 TYR A 394 GLU A 424 1 31 HELIX 14 AB5 HIS A 430 LYS A 438 1 9 HELIX 15 AB6 LEU B 175 PHE B 190 1 16 HELIX 16 AB7 THR B 193 THR B 202 1 10 HELIX 17 AB8 ASP B 215 LEU B 226 1 12 HELIX 18 AB9 LEU B 231 LEU B 235 5 5 HELIX 19 AC1 GLU B 240 SER B 266 1 27 HELIX 20 AC2 ILE B 267 SER B 272 1 6 HELIX 21 AC3 PHE B 274 ALA B 295 1 22 HELIX 22 AC4 ARG B 314 SER B 319 1 6 HELIX 23 AC5 PRO B 323 LEU B 341 1 19 HELIX 24 AC6 ASP B 344 LEU B 357 1 14 HELIX 25 AC7 ASN B 366 HIS B 389 1 24 HELIX 26 AC8 TYR B 394 GLU B 424 1 31 HELIX 27 AC9 HIS B 430 LYS B 438 1 9 SHEET 1 AA1 4 PHE A 211 ILE A 213 0 SHEET 2 AA1 4 GLY A 310 THR A 313 1 O PHE A 311 N ILE A 213 SHEET 3 AA1 4 GLY A 302 VAL A 305 -1 N LEU A 303 O VAL A 312 SHEET 4 AA1 4 VAL A 298 ASN A 299 -1 N ASN A 299 O GLY A 302 SHEET 1 AA2 4 PHE B 211 ILE B 213 0 SHEET 2 AA2 4 GLY B 310 THR B 313 1 O PHE B 311 N ILE B 213 SHEET 3 AA2 4 GLY B 302 VAL B 305 -1 N LEU B 303 O VAL B 312 SHEET 4 AA2 4 VAL B 298 ASN B 299 -1 N ASN B 299 O GLY B 302 LINK C GLN A 250 N CME A 251 1555 1555 1.34 LINK C CME A 251 N THR A 252 1555 1555 1.33 LINK C GLN B 250 N CME B 251 1555 1555 1.33 LINK C CME B 251 N THR B 252 1555 1555 1.33 CISPEP 1 LYS A 322 PRO A 323 0 7.78 CISPEP 2 LYS B 322 PRO B 323 0 1.55 CRYST1 39.560 94.810 96.610 90.00 98.27 90.00 P 1 21 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.025278 0.000000 0.003674 0.00000 SCALE2 0.000000 0.010547 0.000000 0.00000 SCALE3 0.000000 0.000000 0.010460 0.00000